Cargando…
Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia
BACKGROUND: Venous leg ulcers (VLUs) are expensive to treat and impair quality of life of affected individuals. Although improved healing and reduced recurrence rates have been observed following the introduction of evidence-based guidelines, a significant evidence-practice gap exists. Compression i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992639/ https://www.ncbi.nlm.nih.gov/pubmed/29880046 http://dx.doi.org/10.1186/s12913-018-3234-3 |
_version_ | 1783330061586268160 |
---|---|
author | Cheng, Qinglu Gibb, Michelle Graves, Nicholas Finlayson, Kathleen Pacella, Rosana E. |
author_facet | Cheng, Qinglu Gibb, Michelle Graves, Nicholas Finlayson, Kathleen Pacella, Rosana E. |
author_sort | Cheng, Qinglu |
collection | PubMed |
description | BACKGROUND: Venous leg ulcers (VLUs) are expensive to treat and impair quality of life of affected individuals. Although improved healing and reduced recurrence rates have been observed following the introduction of evidence-based guidelines, a significant evidence-practice gap exists. Compression is the recommended first-line therapy for treatment of VLUs but unlike many other developed countries, the Australian health system does not subsidise compression therapy. The objective of this study is to estimate the cost-effectiveness of guideline-based care for VLUs that includes public sector reimbursement for compression therapy for affected individuals in Australia. METHODS: A Markov model was designed to simulate the progression of VLU for patients receiving guideline-based optimal prevention and treatment, with reimbursement for compression therapy, and then compared to usual care in each State and Territory in Australia. Model inputs were derived from published literature, expert opinion, and government documents. The primary outcomes were changes to costs and health outcomes from a decision to implement guideline-based optimal care compared with the continuation of usual care. Sensitivity analyses were performed to test the robustness of model results. RESULTS: Guideline-based optimal care incurred lower total costs and improved quality of life of patients in all States and Territories in Australia regardless of the health service provider. We estimated that providing compression therapy products to affected individuals would cost the health system an additional AUD 270 million over 5 years but would result in cost savings of about AUD 1.4 billion to the health system over the same period. An evaluation of unfavourable values for key model parameters revealed a wide margin of confidence to support the findings. CONCLUSIONS: This study shows that guideline-based optimal care would be a cost-effective and cost-saving strategy to manage VLUs in Australia. Results from this study support wider adoption of guideline-based care for VLUs and the reimbursement of compression therapy. Other countries that face similar issues may benefit from investing in guideline-based wound care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3234-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5992639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59926392018-06-21 Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia Cheng, Qinglu Gibb, Michelle Graves, Nicholas Finlayson, Kathleen Pacella, Rosana E. BMC Health Serv Res Research Article BACKGROUND: Venous leg ulcers (VLUs) are expensive to treat and impair quality of life of affected individuals. Although improved healing and reduced recurrence rates have been observed following the introduction of evidence-based guidelines, a significant evidence-practice gap exists. Compression is the recommended first-line therapy for treatment of VLUs but unlike many other developed countries, the Australian health system does not subsidise compression therapy. The objective of this study is to estimate the cost-effectiveness of guideline-based care for VLUs that includes public sector reimbursement for compression therapy for affected individuals in Australia. METHODS: A Markov model was designed to simulate the progression of VLU for patients receiving guideline-based optimal prevention and treatment, with reimbursement for compression therapy, and then compared to usual care in each State and Territory in Australia. Model inputs were derived from published literature, expert opinion, and government documents. The primary outcomes were changes to costs and health outcomes from a decision to implement guideline-based optimal care compared with the continuation of usual care. Sensitivity analyses were performed to test the robustness of model results. RESULTS: Guideline-based optimal care incurred lower total costs and improved quality of life of patients in all States and Territories in Australia regardless of the health service provider. We estimated that providing compression therapy products to affected individuals would cost the health system an additional AUD 270 million over 5 years but would result in cost savings of about AUD 1.4 billion to the health system over the same period. An evaluation of unfavourable values for key model parameters revealed a wide margin of confidence to support the findings. CONCLUSIONS: This study shows that guideline-based optimal care would be a cost-effective and cost-saving strategy to manage VLUs in Australia. Results from this study support wider adoption of guideline-based care for VLUs and the reimbursement of compression therapy. Other countries that face similar issues may benefit from investing in guideline-based wound care. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3234-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-07 /pmc/articles/PMC5992639/ /pubmed/29880046 http://dx.doi.org/10.1186/s12913-018-3234-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cheng, Qinglu Gibb, Michelle Graves, Nicholas Finlayson, Kathleen Pacella, Rosana E. Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title | Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title_full | Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title_fullStr | Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title_full_unstemmed | Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title_short | Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia |
title_sort | cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in australia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992639/ https://www.ncbi.nlm.nih.gov/pubmed/29880046 http://dx.doi.org/10.1186/s12913-018-3234-3 |
work_keys_str_mv | AT chengqinglu costeffectivenessanalysisofguidelinebasedoptimalcareforvenouslegulcersinaustralia AT gibbmichelle costeffectivenessanalysisofguidelinebasedoptimalcareforvenouslegulcersinaustralia AT gravesnicholas costeffectivenessanalysisofguidelinebasedoptimalcareforvenouslegulcersinaustralia AT finlaysonkathleen costeffectivenessanalysisofguidelinebasedoptimalcareforvenouslegulcersinaustralia AT pacellarosanae costeffectivenessanalysisofguidelinebasedoptimalcareforvenouslegulcersinaustralia |